Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...

The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...